arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Acrivon Therapeutics, Inc.

ACRV

$1.74 ▲ +0.05 (+2.96%) at close

22 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Acrivon Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $67.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -16.5% ↘

FCF / Share $-0.53

Trailing P/E —

Price / Book 0.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-19.04M

↑ +3.2% —

FCF / Share Free cash flow per share

$-0.53

↓ -3.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
EPS Growth YoY (%)	3.9% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	16.9% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	20.3% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-5.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	30.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	32.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	10.6% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	17.5% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	-25.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	87.2% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	80.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	85.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-274.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	3.2% Caution ↑ Caution Improving Year-over-year change in net income	16.8% Good ↑ Good Improving Year-over-year change in net income	-19.4% Weak → Weak Stable Year-over-year change in net income	-19.4% Weak ↑ Weak Improving Year-over-year change in net income	-19.4% Weak ↑ Weak Improving Year-over-year change in net income	-18.6% Weak ↑ Weak Improving Year-over-year change in net income	-29.2% Weak ↑ Weak Improving Year-over-year change in net income	-29.2% Weak ↑ Weak Improving Year-over-year change in net income	-29.2% Weak ↑ Weak Improving Year-over-year change in net income	-115.6% Weak ↓ Weak Declining Year-over-year change in net income	-76.7% Weak ↑ Weak Improving Year-over-year change in net income	-76.7% Weak ↓ Weak Declining Year-over-year change in net income	-76.7% Weak ↓ Weak Declining Year-over-year change in net income	-105.6% Weak Weak Year-over-year change in net income	-4.5% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	-3.9% Weak Weak Year-over-year change in free cash flow	—	—	—	35.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-52.6% Weak Weak Year-over-year change in free cash flow	—	—	—	89.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
FCF / Net Income (x)	1.08x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	1.09x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	—	0.96x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.22x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-16.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-12.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	16.6% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	12.8% Good ↓ Good Declining Return earned on debt + equity capital invested Optimal: > 10%	18.4% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	14.2% Good Good Return earned on debt + equity capital invested Optimal: > 10%	10.7% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-18.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.5% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-14.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-9.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.5% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-5.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-10.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-4.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-19.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-233%)	-16.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-212%)	-15.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-202%)	-13.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-192%)	-12.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-182%)	-12.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-186%)	-8.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-156%)	-7.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-151%)	-15.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-202%)	-15.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-206%)	-9.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-162%)	-8.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-157%)	-7.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-153%)	-5.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-135%)	15.8% Good ↓ Good Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+6%)	19.7% Good ↓ Good Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+32%)	23.3% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+55%)	18.2% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+22%)	35.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+133%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-34.06M	$-41.50M	$-35.41M	$-41.90M	$-39.15M	$-39.82M	$-43.41M	$-46.01M	$-24.61M	$-36.02M	$-29.86M	$-38.07M	$-27.49M	$-29.52M	$-32.08M	$-83.86M	$-90.77M	$-99.60M	$-3.61M	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-0.49	$-0.49	$-0.47	$-0.55	$-0.51	$-0.59	$-0.59	$-0.52	$-0.73	$-0.87	$-0.66	$-0.63	$-0.58	$4.99	$-5.17	$-3.29	$-4.08	$-2.46	$-1.38	—	—	—
Free Cash Flow per Share (USD)	$-0.53	—	$-0.34	$-0.44	$-0.51	—	—	—	$-0.79	—	—	—	$-0.52	—	—	$-3.90	$-4.99	—	—	—	—	—
Book Value per Share (USD)	$2.47	$3.56	$4.08	$4.55	$5.12	$5.66	$6.32	$6.98	$4.77	$5.38	$6.25	$6.76	$7.32	$7.78	$-25.42	$-20.67	$-17.51	$-13.45	$-11.17	—	—	—
Tangible Book Value per Share (USD)	$2.47	$3.56	$4.08	$4.55	$5.12	$5.66	$6.32	$6.98	$4.77	$5.38	$6.25	$6.76	$7.32	$7.78	$-25.42	$-20.67	$-17.51	$-13.45	$-11.17	—	—	—
Basic Weighted Avg Shares (shares)	38.72M	—	38.56M	38.46M	38.35M	—	38.11M	36.13M	22.59M	—	22.08M	21.97M	21.92M	—	1.78M	1.77M	1.77M	—	1.77M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$88.17M	$104.78M	$115.47M	$124.98M	$137.78M	$164.41M	$174.16M	$171.07M	$103.10M	$116.39M	$135.19M	$146.26M	$118.28M	$125.58M	$72.28M	—	—	$97.49M	—	—	—	—
Total Equity (USD)	$95.52M	$112.52M	$128.60M	$143.04M	$160.39M	$176.79M	$196.89M	$216.06M	$107.98M	$121.19M	$138.15M	$149.18M	$160.47M	$170.47M	$-45.62M	$-36.58M	$-30.99M	$-23.81M	$-19.77M	$-17.36M	$-8.41M	$-8.41M

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Depreciation Expense (USD)	$383.00K	$361.00K	$300.00K	$300.00K	$311.00K	$303.00K	$300.00K	$200.00K	$224.00K	$149.00K	$100.00K	$100.00K	$125.00K	$125.00K	$100.00K	$100.00K	$45.00K	$13.00K	$9.00K	—	—	—
Net Income, GAAP (USD)	$-19.04M	$-18.98M	$-19.68M	$-19.68M	$-19.68M	$-22.83M	$-16.49M	$-16.49M	$-16.49M	$-19.25M	$-12.76M	$-12.76M	$-12.76M	$-8.93M	$-7.22M	$-7.22M	$-7.22M	$-4.34M	$-6.91M	—	—	—
Operating Cash Flow (USD)	$-20.54M	$-15.24M	$-12.28M	$-16.61M	$-19.54M	$-17.36M	—	—	$-17.08M	$-12.37M	—	—	$-11.36M	$-9.35M	—	$-5.82M	$-8.42M	$-3.63M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters

Acrivon Therapeutics, Inc.

Analytical Summary

22-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ACRV with peers